Orphan status for Stem Cell’s leukaemia drug – PMLiVE
|
Orphan status for Stem Cell’s leukaemia drug
PMLiVE US regulators have granted orphan drug status to tigecycline, a cancer drug in development by Stem Cell Therapeutics. The designation provided by the Food and Drug Administration (FDA) is granted to drugs under review for use in rare diseases and comes … |
